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Summary 
Bacteria and viruses often use the normal biological properties of host adhesion molecules to 
infect relevant host cells. The outer membrane bacterial protein invasin mediates the attachment 
of Yersinia pseudotuberculosis to human cells. In vitro studies have shown that four members of 
the very late antigen (VLA) integrin family of adhesion molecules, VLA-3, VLA-4, VLA-5, and 
VLA-6, can bind to invasin.  Since CD4 + T  cells express  and use these integrins, we have 
investigated the interaction of CD4 + T  ceils with purified invasin.  Although VLA integrin- 
mediated adhesion of T cells to other ligands such as fibronectin does not occur at high levels 
unless the T  cells are activated,  resting T  cells bind strongly to purified invasin. The binding 
of resting T  ceUs to invasin requires  metabolic activity and an intact cytoskdeton. Although 
CD4 +  T  cells  express  VLA-3,  VLA-4,  VLA-5,  and  VLA-6,  monoclonal antibody  (mAb) 
blocking studies implicate only VLA-4 as a T call invasin receptor.  Like other integrin ligands, 
invasin can facilitate T call proliferative responses induced by a CD3-specific mAb. These results 
suggest that the nature of the integrin llgand is a critical additional factor that regulates T cell 
integrin activity, and that direct interactions of T cells with bacterial pathogens such as Yersinia 
may be relevant  to host immune responses  to bacterial  infection. 
T 
he immune response is dependent on the physical inter- 
action of its various cellular members with each other 
and with the surrounding microenvironment (1). Integrins 
are a large family of c~//3 heterodimeric  proteins that mediate 
the adhesion of many different cell types to other cells and 
to components of the extracellular  matrix (ECM)  such as 
fibronectin (FN), laminin, and collagen (1-3).  Since T cells 
must be  able  to  rapidly  alternate  between  adhesive  and 
nonadhesive states, the functional activity ofintegrins expressed 
on T ceils is tightly regulated. T cell activation rapidly modu- 
lates the functional activity of four intega'ins expressed on 
peripheral T  ceUs: the/32 integrin LFA-1 and the B1 inte- 
grins very late antigen (VLA)-4 (abo designated cx4/31), VLA-5 
(oeSB1), and VLA-6 (o~6/31). Whereas resting T cells demon- 
strate minimal integrin-mediated adhesion, activation results 
within minutes in strong T cell adhesion to integrin ligands 
without a change in the level of cell surface expression  of 
the integrin receptors themsdves (4-6). Multiple activation 
signals can induce this rapid change in integrin activity, in- 
cluding treatment with the phorbol ester PMA, the Ca  2+ 
ionophore A23187, mitogenic pairs of CD2-specific  mAbs, 
mAb cross-linking of the CD3-TCR complex, or mAb cross- 
linking of the T cell surface molecules CD7, CD28, or CD31 
(4-8).  To date, this dependence on activation for strong T 
cell integrin function has been demonstrated for all of the 
integrin ligands tested, including the LFA-1 ligand intercel- 
lular adhesion molecule I (ICAM-1), the VLA-4 cell surface 
ligand vascular cell adhesion molecule (VCAM)-I, the VLA- 
4  and VLA-5  ligand FN,  and the VLA-6 ligand laminin 
(4-7, 9). 
Whereas adhesion molecules play a fundamentally critical 
role in immune system function, their adhesive properties 
are often used by bacteria  and viruses  as a means of entry 
and survival in the host organism (10, 11). Recent studies 
of the intracellular bacterial pathogen Yersinia pseudotubercu- 
losis have shown that the bacterial outer membrane protein 
invasin mediates the attachment and internalization of Yer- 
sinia by normally nonphagocytic cells by binding to four 
different VLA integrins: VLA-3, VLA-4, VLA-5, and VLA-6 
(12, 13). Since CD4 + T ceils express all of these VLA inte- 
grins (6), and VLA-4 in particular is expressed predominantly 
by lymphoid cells (2), we hypothesized that the interaction 
of T cells with invasin may be critical to our understanding 
of integrin function and immune responses to this bacterial 
pathogen. We show in this study that: (a) strong T call binding 
to invasin occurs without activation, unlike binding to all 
207  J. Exp.  Meal. ￿9  The Rockefeller  University Press ￿9 0022-1007/93/01/0207/06  $2.00 
Volume  177  January 1993  207-212 other T cell integrin ligands tested to date; (b) the predomi- 
nant invasin receptor on CD4 + T cells is VLA-4; and (c) in- 
vasin can facilitate CD3-mediated T cell proliferative responses. 
Materiah and Methods 
Human  T  Cells.  Peripheral CD4 + T  cells were isolated by 
negative  magnetic immunosdection from either leukapheresis  packs 
or buffy coats as previously  described  (6, 7, 14). The T cell popula- 
tions were typically >96% CD3+CD4 + as assessed by flow cyto- 
metric analysis.  Complete depletion of  monocytes  in the T cell  prep- 
aration was determined by the lack of proliferative response to 
optimal concentrations (1:200 dilution) of PHA (M form) (Gibco- 
BRL, Grand Ishnd, NY). 
Antibodies and Other Reagents.  The following mAbs were used 
as purified IgG: anti-CD3 mAb OKT3, anti-CD7 mAb 3A1, and 
anti-LFA-1 cz chain mAb TS1/22 (American Type Culture Collec- 
tion, Rockvilh, MD); anti-VLA-5 c~ chain mAb MAB16 (15) and 
anti-VLA/3 chain mAB MAB13 (15) (provided  by Dr. K. Yamada, 
National Institutes of Health [NIH],  Bethesda, MD); and anti- 
VLA-4 cr chain mAb NIH49d-1 (8) (Drs. S. Shaw and Y. Tanaka, 
NIH). The following mAbs were used as dilutions of ascites fluid: 
anti-CD28 mAb 9.3 (J. Ledbetter, Bristol Myers Squibb, Seattle, 
WA); anti-CD2 mAbs 95-5-49 and 9-1 (Dr. R Dupont, Memorial 
Sloan Kettering Cancer Center, New York, NY); anti-VLA-3 ot 
chain mAb P1B5, anti-VLA-5  ot chain mAb P1D6, and anti-VI.A-4 
c~ chain mAb P4G9 (Telios Pharmaceuticals,  Inc., San Diego, CA); 
and anti-VLA-4  ot chain mAb L25 (16) (Dr. P. Estess, Becton Dick- 
inson & Co., Mountain View, CA). The following mAbs were 
used as dilutions of culture supematant: anti-VLA-6  ,v chain mAb 
GoH-3 (Dr. A. Sonnenberg, Central Laboratory of the Nether- 
lands Red  Cross Blood Transfusion Service, Amsterdam, The 
Netherlands); anti-V'l.A-5 ry chain mAbs BIIG2 and B1E5, and anti- 
VLA B chain mAb AIIB2 (Dr. C. Damsky, University  of  California, 
San Francisco,  CA); the anti-V'LA-4  c~ chain mAbs HP2/1, HP1/2, 
HP2/4,  HP1/1,  HP1/7 (17), and the anti-VLA B chain mAbs 
LIA1/2, ALEX1/4, LIA1/5, and TS2/16 (18) (kindly provided by 
Dr. E Sanchez-Madrid,  Universidad  Autonoma de Madrid, Madrid, 
Spain). 
The invasin utilized in this study is a fusion protein consisting 
of the COOH-terminal end of invasin (479 amino acids in length) 
and maltose  binding protein (MBP) (13). MBP and collagen  (Sigma 
Chemical Co., St. Louis, MO) were used as negative control pro- 
teins. FN was purchased from the New York Blood Center (New 
York, NY). Cytochalasin B was purchased from Sigma Chemical 
Co., and stanrosporin was purchased from Boehringer Mannheim 
Diagnostics (Indianapolis, IN). Both were dissolved  in DMSO be- 
fore use. Dibutyryl cAMP (Calbiochem-Behring  Corp., San Diego, 
CA) was dissolved in PBS before use. 
Adhesion Assays.  Adhesion  assays  were performed as described 
(6, 7). Each well contained 50,000 SlCr-labded T ceils in a final 
volume of 0.1 ml PBS/0.5% HSA. For PMA activation, cells were 
added to wells containing 10 ng/ml PMA (Sigma Chemical Co.). 
All data are expressed as the mean percent of ceUs binding from 
three replicate wells plus SEM. In all mAb blocking experiments, 
mAbs were added to wells at 10/~g/ml (for purified IgG), 1:500 
dilution (for ascites fluid) or 1:5 dilution (for culture supematants). 
Inhibitors were present throughout the assay  at the concentrations 
indicated. 
T Cell Proliferation  Assays.  Proliferation assays  were performed 
essentially  as previously  described (19). During the last 18 h of the 
assay, the culture was pulsed with 1 #Ci/well of pH]thymidine 
(New England Nuclear/Dupont,  sp act of 6.7 Ci/mmol). Results 
are expressed as the arithmetic mean cpm of triplicate cultures. Mi- 
crotiter plates (Costar Corp., Cambridge, MA) were prepared by 
first incubating indicated concentrations of the CD3 mAb OKT3 
overnight at 4"C in PBS, washing away the unbound mAb, and 
adding the indicated concentrations of invasin or FN (diluted in 
PBS with Ca  2§  and Mg  2+) for an addition 2-3 h incubation at 
room temperature. Plates were washed three times with PBS be- 
fore the start of culture, mAbs were added at the same concentra- 
tions used in the adhesion assays, except for culture supernatants, 
which were used at a 1:8 final dilution. 
Results 
Binding of Resting As Well As Activated  T  Cells To Purified 
Invasion.  Previous studies have shown that strong adhesion 
of human CD4 + T cells to relevant VLA ligands such as FN 
(via VLA-4 and VLA-5), laminin (via VLA-6), and VCAM-1 
(via VLA-4) requires  activation of the T  cell by a stimulus 
such as PMA (6,  7,  9).  In contrast to the results obtained 
with these previously described VLA integrin ligands, resting 
CD4 +  T  ceUs bound  strongly and  in  a  dose-dependent 
fashion to purified invasin (Fig.  1). Treatment of T cells for 
10 min with 10 ng/ml PMA dramatically increased adhesion 
to FN, but only slightly increased adhesion to invasin (Fig. 
1). An increase in binding to invasin after PMA activation 
of T cells was most evident at low doses of immobilized in- 
vasin. Similar results were obtained after activation ofT cells 
with  other  stimuli  that  increase  VLA  integrin-mediated 
binding to FN (6,  7,  and data not shown). 
VLA-4 Is the Predominant Integrin Inmsin Receptor on Human 
T Cells.  mAb blocking studies were performed using a large 
panel of VLA [3 chain- and VLA ot chain-specific mAbs. 
The data in Fig. 2 show that the VLA [3 chain-specific mAb 
AIIB2, which has previously been shown to block the binding 
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Figure  1.  Binding of resting and PMA-activated CD4 § T cells to 
purified invasin. Binding  of slCr-hbded CD4 + T cens to purified  invasin, 
MBP, or FN (applied at the indicated  concentrations)  after  no activation 
(open squares) or after  activation  for 10 rnin at 37~  with 10 ng/ml PMA 
(solid squares). Binding of resting and PMA-aetivated  T cells to collagen 
was <8%. Data  are representative  of a minimum  of four  experiments  with 
different donors. 
208  T Cell Interactions  with Invasin Figure  2.  mAb blocking ofT cell adhesion to invasin by VLA a chain 
and VLA/3 chain mAbs. Binding of  resting (solid bars) and PMA-activated 
(shaded bars) CD4 § T cells to invasin (added at 30 ng/well) was assessed 
in the continuous presence of the indicated mAbs. Binding of resting and 
PMA-activated T cells to either collagen or MBP was <5%. Data are rep- 
resentative  of a minimum of three experiments  with different  donors. 
of the erythroleukemia  cell line K562 to invasin (12), can also 
completely inhibit T  cell adhesion to invasin.  In addition, 
two other VLA/3 chain-specific mAbs, LIAI/2 and MAB13, 
can inhibit T  cell adhesion to invasin. Three other VLA/3 
chain-specific mAbs only partially inhibit T cell adhesion to 
invasin,  suggesting that these mAbs recognize epitopes on 
the VLA/3 chain that are minimally involved in binding to 
invasin. 
Studies with various VLA c~ chain-specific mAbs demon- 
strate that one VLA-4 tx chain-specific mAb, HP1/2,  can 
inhibit T cell adhesion to invasin as effectively as the inhibi- 
tory VLA/3 chain-specific mAbs (Fig. 2). A panel of VLA-5 
a  chain-specific mAbs, all of which inhibit cell adhesion to 
FN, did not inhibit T  cell adhesion to invasin.  This panel 
includes one VLA-5-specific  mAb (BIIG2) that was previ- 
ously shown to inhibit the binding of K562 cells to invasin 
(12). In addition, the VLA-3 oe chain-specific mAb PLB5 and 
the VLA-6 c~ chain-specific mAb GoH-3, both of which are 
functionally inhibitory mAbs (6,  20, and Y. Shimizu, un- 
published results), did not inhibit T cell adhesion to invasin. 
Thus, these data strongly suggest that VLA-4 is the predom- 
inant invasin receptor on human T  cells. 
Binding  of Resting  T  Cells to Invasin Requires Metabolic Ac- 
tivity and an Intact Cytoskeleton.  We assessed the ability of 
various metabolic inhibitors to inhibit the binding of resting 
T  cells to invasin as a first test of whether engagement by 
invasin generates intracellular signals that might rapidly up- 
regulate VLA integrin activity.  The data in Fig. 3 demon- 
strate that the increased adhesion to invasin observed with 
Figure  3.  Binding of resting T cells to invasin requires metabolic ac- 
tivity and an intact cytoskeleton.  Binding of CD4 + T cells was assessed 
as described in Materials  and  Methods.  Invasin was immobilized at 30 
ng/well in both experiments  shown.  This suboptimal  amount of invasin 
was chosen to maximize the differences in binding between resting and 
PMA-activated  T  cells. For dibutyryl cAMP. T  ceils were preincubated 
for 30 min at 37~  Each of the indicated inhibitors was present throughout 
the adhesion  assay. Staurosporin  was used  at a final concentration of 1 
#M, dibutyryl cAMP at 3 mM, sodium azide at 0.1%,  cytochalasin B 
at 5 #g/ml, and EDTA at 5 raM. Data are representative of a minimum 
of three experiments  testing each inhibitor. 
PMA-activated T cells can be inhibited to the level of resting 
T  cell  binding by the protein kinase C  (PKC)  inhibitor 
staurosporin. However, staurosporin did not inhibit resting 
T cell adhesion to invasin, suggesting that adhesion of resting 
T cells to invasin is not dependent on PKC activation.  Treat- 
ment of T cells with the cAMP analogue dibutyryl cAMP, 
which has been shown to inhibit activation-dependent T cell 
adhesion to FN and ICAM-1 (4, 7), or the tyrosine kinase 
inhibitor herbimycin A also did not inhibit the binding of 
resting T cells to invasin (Fig. 3 and data not shown). How- 
ever, treatment of T cells with sodium azide significantly in- 
hibited invasin binding by resting T  cells, suggesting that 
T  cell adhesion to invasin requires  a metabolically active T 
cell. Furthermore, the ability of the cytoskeletal disrupting 
agent cytochalasin B to inhibit the binding of both resting 
and PMA-activated  T cells to invasin is consistent with ear- 
lier data implicating the cytoskeleton in integrin-mediated 
adhesive events (21). Treatment of T  cells with EDTA also 
abolishes T cell binding to invasin, consistent with the diva- 
lent cation requirements of integrin receptors. 
Invasin Facilitates CD3-raediated  T  Cell Proliferation.  The 
interaction of VLA integrins with a relevant ligand can also 
facilitate T  call proliferative  responses.  This has been most 
effectively demonstrated in an in vitro system where purified 
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Figure 4.  Purified invasin facilitates  CD3-mediated T cell proliferation. 
Proliferative responses of CD4 + T  cells were  assessed as described in 
Materials and Methods. Microtiter wells were coated with either no OKT3 
mAb (open squares), 0.1/~g/well OKT3 (solid squares), 0.3/~g/well OKT3 
(solid triangles), or 1/~g/well OKT3 (solid circles) and then the indicated 
amount of invasin before wells were washed and cells added. [3H]Thymi- 
dine incorporation by T cells in the absence of any additional stimulus 
was 2361 cpm (donor.~9747) and 579 cpm (donor 39702) and has not been 
subtracted from the data shown. Thymidine incorporation by T ceils in 
the presence of PHA (1:200 dilution) was 3,053 cpm (donor 39747) and 
880 cpm (donor 39702).  Thymidine incorporation by T cells to any con- 
centration of OKT3 alone tested (or a combination of OKT3 and MBP) 
was <2,060 cpm (donor 39747)  and 1,767 cpm (donor .~9702). Data are 
representative of a minimum of four different experiments with different 
donors. 
T  cells are activated  through the CD3-TCR by the CD3- 
specific mAb OKT3 immobilized on plastic. In the absence 
of accessory cells, human T cells fail to proliferate in response 
to immobilized CD3 mAb alone (9, 19). However, vigorous 
T cell proliferation occurs when a VLA integrin ligand, such 
as FN, laminin, or VCAM-1, is coimmobilized  with the CD3 
mAb (9, 15, 19, 22). Fig. 4 shows that as with other VLA 
integrin ligands, coimmobilization of invasin with the CD3 
mAb OKT3 can also result in T cell proliferation. The same 
VLA4 o~ chain- and VLA/~ chain-specific mAbs that in- 
hibit T  cell adhesion to invasin (Fig.  2) also inhibit T  cell 
proliferation induced by coimmobilized  invasin and CD3 mAb 
(data  not shown). 
Discussion 
We have shown in this study that human CD4 + T cells 
bind via VLA integrins to the bacterial protein invasin. How- 
ever, unlike other VLA integrin ligands, there is strong adhe- 
sion of resting T  cells to invasin with a relatively small in- 
crease in the overall strength of adhesion after  modes of 
activation that dramatically increase T cell adhesion to other 
integrin ligands such as FN, VCAM-1, and laminin. Thus, 
these findings illustrate an important additional regulatory 
component to integrin receptors. Other properties common 
to integrin ligands,  such as the ability to facilitate  CD3- 
mediated T cell proliferative responses (Fig. 4), are also ex- 
hibited by invasin. 
The exact mechanism by which invasin promotes such vig- 
orous adhesion of resting T calls to invasin currently remains 
undefined. One possibility is that the high affinity of invasin 
for its VLA integrin receptors can overcome the low func- 
tional activity ofVLA integrins on resting T cdlL This mech- 
anism would suggest that any integrin ligand with suf~dently 
high atfinity would be able to mediate the adhesion of resting 
T cells. A second possibility is that binding of resting T cells 
to invasin results in the generation of a signal that upregn- 
lutes VLA integrin activity. This hypothesis is supported in- 
directly by: (a) the requirement for a metabolically active T 
call to observe binding to invasin (Fig. 3); and (b) numerous 
reports of mAbs directed against the VLA-4 ot chain or the 
VLA/3 chain that can upregnlate adhesion to relevant ligands 
(17, 18, 23-25). We are continuing to investigate the poten- 
tial of invasin as an integrin regulatory molecule. Neverthe- 
less, our results dearly illustrate that in addition to the al- 
ready well established role of activation in regnlating T cell 
integrin function, the nature of the ligand itsdf also plays 
an important role in regulating adhesion. Thus, integrin- 
mediated adhesion to distinct ligands can be regulated in very 
different ways. 
mAb blocking studies indicate that the VLA-4 integrin 
is the predominant invasin receptor on CD4 + T cells (Fig. 
2). Even though CD4 + T cells express VLA-3, VLA-5, and 
VLA-6, and these VLA integrins have previously been shown 
to bind to invasin (12), we were unable to identify any mAbs 
specific for VLA-3, VLA-5, or VLA-6 that were able to in- 
hibit T cell binding to invasin. This may be due to the higher 
levels of VLA-4 expressed on CD4 + T cells compared with 
VLA-3, VLA-5, and VLA-6 (6). However, the contribution 
of specific VLA integrins to adhesion to a specific ligand does 
not always correlate with the levd of integrin expression. For 
example, T cell adhesion to FN is mediated predominantly 
by VLA-5, even though it is expressed at lower levels on T 
cells than VLA-4, which also binds FN (6). There may also 
be cell type-specific differences in the ligand specificity of in- 
dividual VLA integrins since VLA-2 has  been  shown to 
differentially recognize laminin depending upon the specific 
type of cell in which VLA-2 is expressed (26).  Thus, it is 
conceivable that VLA-3,  VLA-5,  and VLA-6 on human T 
cells do not function as invasin receptors as they do on other 
cell types that express these receptors.  The inability of the 
VLA-5-specific mAb BIIG2 to inhibit T cell binding to in- 
vasin is consistent with this hypothesis, since this mAb was 
previously shown to inhibit the binding of K562 cells to in- 
vasin (12). 
Although enteropathogenic bacteria such as Yersinia are 
thought to mainly interact with epithelial and other connec- 
tive tissue cells, T  cell interactions with bacteria  may also 
be relevant to our understanding of bacterial pathogenicity. 
Our results suggest that invasin allows Yersinia to potentially 
interact with any human cells that express the appropriate 
VLA integring even cells that normally express these receptors 
in a low activity functional state. This strategy allows invasin- 
bearing bacteria  to overcome the normal mechanisms that 
regulate integrin functional activity.  The ability of invasin 
to facilitate CD3-mediated T cell proliferation (Fig. 4) sug- 
gests that Yersinia might also be able to modulate the im- 
210  T  Ceil Interactions with Invasin mune response in vivo by VLA integrin-mediated  interac- 
tions with invasin.  Our data,  coupled with other indirect 
lines of evidence such as localization of Yersinia to anatomic 
sites rich in T cells such as Peyer's patches (27) and the isola- 
tion of Yersinia-specific T  cell clones (28), suggest that fur- 
ther investigation of the significance of lymphocyte interac- 
tions with bacterial pathogens  is warranted. 
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